For example, the first tyrosine kinase inhibitor, imatinib, was reported to prevent the activation of platelet-derived growth factor receptor (PDGFR), which is often overexpressed in cervical cancer [4], thus inhibiting cervical cancer cell proliferation. Here, PDGFRB is linked to cervical carcinoma.